Dulaglutide is a novel long-acting GLP-1 receptor agonist, which has the function of glucose-dependent promotion of insulin secretion, and can reduce the risk of hypoglycemia compared with insulin therapy. The gene discussed is INS; the disease is Hypoglycemia.